Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Preclinical toxicity study results for Pyridorin will support planned IND filing

Nov. 9, 2015

Quark Pharmaceuticals plans new trials of QPI-1002

Nov. 3, 2015

Isis Pharmaceuticals begins phase II study of ISIS-FXIRx in end-stage renal disease

Nov. 3, 2015

Taiho starts phase I trial of TAS-303 in women with stress urinary incontinence

Nov. 3, 2015

Revive Therapeutics' bucillamine receives orphan drug designation for cystinuria

Oct. 30, 2015

Researchers devise mouse model of nocturnal polyuria

Oct. 26, 2015

AF-219 improves symptoms in patients with interstitial cystitis/bladder pain syndrome

Oct. 26, 2015

Cinryze receives FDA fast track designation

Oct. 14, 2015

Astellas Pharma describes prostanoid EP4 antagonists

Oct. 14, 2015

New financing round at Pharmalink to fund development of phase III program for Nefecon

Oct. 6, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...